Abstract
There is a growing interest in vaccines for intranasal administration due to the advantages of this route in terms of bioavailability, self-administration and because it is a non-invasive route. In addition, for mucosal-associated pathologies, such as mucosal cancer, the intranasal administration contributes to mucosal and systemic immunity. However, the development of an intranasal vacci…